Ftse Mib
38.779,67
0,00%
DAX
23.419,48
1,30%
S&P 500
5.738,52
-1,78%
NASDAQ
18.069,26
-2,61%
Bitcoin
88.011,52
-2,14%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NextCure Inc (NXTC) NextCure Inc (NXTC) Notizie

NXTC

NextCure (NXTC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NXTC
DataOraFonteTitoloSimboloCompagnia
06/03/202522:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
14/02/202519:40Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
06/02/202522:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
04/02/202500:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXTCNextCure Inc
03/02/202522:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXTCNextCure Inc
10/01/202514:05GlobeNewswire Inc.NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersNASDAQ:NXTCNextCure Inc
10/12/202414:05GlobeNewswire Inc.NextCure Announces Acceptance of IND Application for LNCB74NASDAQ:NXTCNextCure Inc
26/11/202413:00GlobeNewswire Inc.NextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
19/11/202414:05GlobeNewswire Inc.Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNASDAQ:NXTCNextCure Inc
15/11/202400:59Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:NXTCNextCure Inc
07/11/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXTCNextCure Inc
07/11/202422:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
05/11/202422:05GlobeNewswire Inc.NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
04/10/202415:05GlobeNewswire Inc.NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:NXTCNextCure Inc
16/09/202414:05GlobeNewswire Inc.NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024NASDAQ:NXTCNextCure Inc
01/08/202422:05GlobeNewswire Inc.NextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
20/06/202422:10GlobeNewswire Inc.NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:NXTCNextCure Inc
30/05/202422:05GlobeNewswire Inc.NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024NASDAQ:NXTCNextCure Inc
02/05/202422:05GlobeNewswire Inc.NextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:NXTCNextCure Inc
24/04/202422:05GlobeNewswire Inc.NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024NASDAQ:NXTCNextCure Inc
08/04/202413:00GlobeNewswire Inc.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024NASDAQ:NXTCNextCure Inc
04/04/202413:05GlobeNewswire Inc.NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardNASDAQ:NXTCNextCure Inc
02/04/202413:00GlobeNewswire Inc.NextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:NXTCNextCure Inc
21/03/202413:55GlobeNewswire Inc.NextCure Provides Business Update and Reports Full Year 2023 Financial ResultsNASDAQ:NXTCNextCure Inc
05/03/202414:05GlobeNewswire Inc.NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesNASDAQ:NXTCNextCure Inc
18/01/202422:05GlobeNewswire Inc.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersNASDAQ:NXTCNextCure Inc
21/12/202313:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryNASDAQ:NXTCNextCure Inc
14/12/202312:45GlobeNewswire Inc.NextCure Provides Year-End Clinical Pipeline UpdatesNASDAQ:NXTCNextCure Inc
20/11/202313:00GlobeNewswire Inc.NextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:NXTCNextCure Inc
15/11/202322:05GlobeNewswire Inc.NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNASDAQ:NXTCNextCure Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NXTC

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci